BioGaia AB

📨📢 Latest news from #BioGaia: #Anatom Holding AG #acquires 4.9% stake in BioGaia This week, BioGaia AB announced that Switzerland-based investment firm Anatom Holding AG has acquired 4,979,813 class B shares in BioGaia AB following the exit of #EQT Public Value fund. This acquisition represents 4.9% of BioGaia’s total shares and 3.7% of the total voting rights. The acquisition was completed on October 31, 2024, and is not subject to any conditions. For full details, read the press release: https://lnkd.in/dxw-yydg

🌍 #BioGaia is a proud partner to the Milkywire #ClimateTransformationFund. Since 2021, the fund has allocated over $14M to support 49 innovative projects across 27 countries. Learn more about the impact in their 2024 Progress Report:

🎥 Theresa Agnew, #BioGaia’s President and CEO, was interviewed this morning on EFN Ekonomikanalen about our #Q3 #results. Watch the #interview here (in English):

🗓 📈 📉 Today we released our Q3 report! Executive summary: * Sales were 304 MSEK (-4%) mainly due to weak sales in EMEA. * Sales in EMEA decreased by 27% and in APAC sales increased by 24%. Americas increased by 5%. * EBIT 41 MSEK (-65%) and EBIT margin 14% (38%). * Adjusted EBIT 93 MSEK (-22%) and Adjusted EBIT margin 31% (38%). Items affecting comparability in the quarter primarily include an impairment loss attributed to the MetaboGen acquisition of 51.2 MSEK. In the CEO´s comment, Theresa Agnew writes: "Over the quarter, we have experienced a mix of results. While certain areas have performed below our expectations, we are pleased with key successes in establishing direct presence in Australia, scaling up our business in Canada, record-breaking sales in the online sales channel in USA, strong growth in China and strong performance of our adult portfolio. Despite these short-term fluctuations in the quarter, we remain confident in our long-term strategy and the solid foundation we are building for sustainable growth." Read the full report here: https://lnkd.in/d-4acEYa

UEG Week in Vienna: A Huge Success! We are wrapping up after an amazing UEG (United European Gastroenterology) week in Vienna, where BioGaia received overwhelming interest from 12,000 participants eager to learn more about our products within gut health; Protectis and Gastrus. A special highlight was having Professor Francisco Guarner and Professor Magnus Simrén join us at our booth. Their insightful mini-lectures on probiotics, IBS, and our upcoming BioGaia Expert Program in GI Health were a big hit. We are extremely proud to have both Francisco and Magnus as medical experts in the program! Learn more and sign up for our Expert Program in GI Health here: https://lnkd.in/dys3PtfW Thank you to everyone who visited our booth and showed interest in our products and research! 🔬 💊 We are leaving Vienna with a good gut feeling 😉. #UEGWeek #UEGWeek2024 #Probiotics #guthealth #IBS

👩⚕️Are you a healthcare professional (HCP)? 💻📚 BioGaia has launched a new educational website for healthcare professionals, including valuable insights and up-to-date information on probiotics. Stay informed and expand your expertise in this rapidly evolving field: https://lnkd.in/g2e5wkNb #BioGaia #Probiotics #HCP #Professionals #Education

📲 🌱 Stay informed with the latest news from #BioGaia AB! As a publicly listed company in the field of probiotics, we are committed to keeping our investors, partners, community, and more informed about our latest innovations, financial results, and important company updates. 📩 Sign up for BioGaia’s press releases to: Get updates on our financial performance 📊 Read the latest news about our probiotic research 🔬 Discover our new product launches 💊 Stay in the loop on our global expansion and strategic milestones 🌍 👉 https://lnkd.in/dc8_cerf #PressRelease #InvestorRelations #CompanyUpdates #StockMarket #CorporateNews

📽 Who are we, what do we do, and why do we do it? Watch BioGaia’s corporate video: https://lnkd.in/d7q3pQwN #BioGaia #SupportingYourInvisibleHeroes #Corporatevideo

📣 Today we released our Q2 2024 report! 📑 Here is the executive summary: • Sales were 384 MSEK ( 22%) mainly driven by sales growth in APAC and Americas • Sales in EMEA increased by 7%, in APAC by 49%, and in Americas by 22% • EBIT 135 MSEK ( 42%) and EBIT margin 35% (30%) • BioGaia established its own distribution in Australia and New Zealand • In early July, BioGaia won the arbitration with the former Italian distributor, Noos • Ramp up investments to drive continued growth. Costs are projected at SEK 75-85 million in the second half of 2024, on top of normal operating costs. Theresa Agnew, President and CEO at BioGaia, writes in her CEO statement: "I am confident about our decision to ramp up investments to drive continued growth, starting in H2 2024, and building on our already strong foundation. The investments follow our company strategy and will include: 1) targeted investments in consumer marketing to bolster awareness and brand recognition, 2) further expansion in established direct markets, such as the USA and Canada, while at the same time developing newer direct markets like Australia and New Zealand and 3) more investments in R&D to further differentiate our products from competitors. We will continue to prioritize markets with significant potential, including the US, the world’s largest probiotics market, as well as Canada and Australia, both ranked in the top 15 globally." Read the full Q2 report, listen to our media and analyst call, and download the investor presentation at: https://lnkd.in/duh2dvSN #BioGaia #q2 #financialreport #Qreport

#BioGaia’s participation at #Medical #Congresses during the spring of 2024: #EPA/ #UNEPSA, #PPPP, and #ESPGHAN During the spring, BioGaia participated in three significant medical meetings and congresses within pediatric health, focusing on our products BioGaia #Protectis Baby Drops and BioGaia #Pharax Kids. EPA/UNEPSA: The 11th European Pediatric Association (EPA/UNEPSA) biennial meeting was held from April 17-21 in Antalya, Turkey. This event marked BioGaia's debut at the meeting, where we were the sole probiotic company represented. We engaged with professionals in the general pediatric health community and presented our key products at our booth. Additionally, BioGaia hosted a scientific symposium titled “Management of Common Infections and Functional Gastrointestinal Disorders Using Evidence-Based Probiotics,” featuring eminent speakers Prof. Flavia Indrio and Prof. Metehan Özen. PPPP: The 9th International Congress on Probiotics, Prebiotics, and Postbiotics in Pediatrics (PPPP) took place from April 25-28, also in Antalya, Turkey. This meeting attracts top researchers and clinicians specializing in microbiome research and probiotic use. BioGaia attended alongside our Turkish partner, Eczacıbaşı. BioGaia’s Chief Scientific Officer, Gianfranco Grompone, presented on a futuristic topic: “A Translational Journey Within the Holobiont: Recent Data from L. reuteri to Next-Generation Probiotics.” This was followed by Prof. Ener Cagri Dinleyici, who presented clinical data on “Probiotics to Fight Antibiotic-Induced Dysbiosis and Infections: The Case of L. reuteri DSM 17938.” ESPGHAN: The European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN), the largest pediatric congress within pediatric gastroenterology, was held in Milan, Italy, from May 17-21. This year’s meeting attracted 5,600 participants (5,300 in person and 300 online) from around the world. Our booth saw high interest in probiotics and our products, with approximately 1,000 visitors over the three days. We were joined by our Italian partner, Recordati. 📣 Upcoming Events In the fall, BioGaia will attend: United European Gastroenterology Week (#UEG Week), October 12-15 in Vienna, Austria, where our focus will be on our Gastrus products. We will engage with physicians specializing in gastrointestinal health for adults. 7th World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition (#WCPGHAN), December 4-7 in Buenos Aires, Argentina. Here, we will connect with pediatricians specializing in gastroenterology and nutrition, promoting Protectis throughout childhood with a focus on clinical data for functional abdominal pain in children. We hope to see you there!